Amundi Has $1.46 Million Stake in Vericel Co. (NASDAQ:VCEL)

Amundi increased its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 184.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,568 shares of the biotechnology company's stock after acquiring an additional 15,936 shares during the quarter. Amundi's holdings in Vericel were worth $1,463,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of VCEL. FMR LLC increased its holdings in shares of Vericel by 1.0% during the 3rd quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company's stock worth $100,251,000 after purchasing an additional 22,461 shares during the period. Congress Asset Management Co. increased its holdings in shares of Vericel by 12.6% during the 4th quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock worth $79,847,000 after purchasing an additional 162,419 shares during the period. GW&K Investment Management LLC increased its holdings in shares of Vericel by 2.4% during the 4th quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company's stock worth $69,953,000 after purchasing an additional 30,180 shares during the period. Geode Capital Management LLC increased its holdings in shares of Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock worth $48,768,000 after purchasing an additional 9,613 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Vericel by 4.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company's stock worth $45,590,000 after purchasing an additional 47,108 shares during the period.

Remove Ads

Insider Buying and Selling at Vericel

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Dominick Colangelo sold 26,592 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the transaction, the chief executive officer now owns 259,997 shares in the company, valued at $11,902,662.66. The trade was a 9.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock worth $1,683,582 over the last ninety days. Corporate insiders own 5.20% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on VCEL shares. BTIG Research upped their target price on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group upped their target price on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, Truist Financial reissued a "buy" rating and issued a $61.00 target price (down previously from $67.00) on shares of Vericel in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $62.29.

Vericel Stock Down 1.9 %

NASDAQ:VCEL traded down $0.92 on Friday, reaching $46.26. The stock had a trading volume of 830,229 shares, compared to its average volume of 376,485. The company has a market capitalization of $2.31 billion, a P/E ratio of 771.13 and a beta of 1.78. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00. The stock has a fifty day moving average price of $54.40 and a 200-day moving average price of $51.68.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.